These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 35598501)
1. A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder. Brar J; Sidana A; Chauhan N; Bajaj MK J Psychiatr Res; 2022 Jul; 151():439-444. PubMed ID: 35598501 [TBL] [Abstract][Full Text] [Related]
2. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014 [TBL] [Abstract][Full Text] [Related]
3. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy. Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440 [TBL] [Abstract][Full Text] [Related]
4. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636 [TBL] [Abstract][Full Text] [Related]
5. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090 [TBL] [Abstract][Full Text] [Related]
6. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617 [TBL] [Abstract][Full Text] [Related]
7. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
8. Intact short-term memory and impaired executive functions in obsessive compulsive disorder. Demeter G; Racsmány M; Csigó K; Harsányi A; Németh A; Döme L Ideggyogy Sz; 2013 Jan; 66(1-2):35-41. PubMed ID: 23607228 [TBL] [Abstract][Full Text] [Related]
9. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB; Gorfinkle KS; Liebowitz MR J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976 [TBL] [Abstract][Full Text] [Related]
10. Neuropsychological performance in medicated vs. unmedicated patients with obsessive-compulsive disorder. Mataix-Cols D; Alonso P; Pifarré J; Menchón JM; Vallejo J Psychiatry Res; 2002 Apr; 109(3):255-64. PubMed ID: 11959362 [TBL] [Abstract][Full Text] [Related]
11. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder. Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580 [TBL] [Abstract][Full Text] [Related]
12. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362 [TBL] [Abstract][Full Text] [Related]
13. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922 [TBL] [Abstract][Full Text] [Related]